Stockscreener 앱 받기
0.7678
10.32%
0.0718
시간 외 거래:
.76
-0.0078
-1.02%
Zhengye Biotechnology Holding Ltd 주식(ZYBT)의 최신 뉴스
AI Models Turn Less Negative on ZYBT but Keep Risk Warnings in Place - TipRanks
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Zhengye Biotechnology Holding Ltd (ZYBT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Zhengye Biotechnology Holding Ltd (ZYBT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Zhengye Biotechnology Holding Ltd (ZYBT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Zhengye Biotechnology Holding Ltd (ZYBT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Zhengye Biotechnology Holding Ltd (ZYBT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Zhengye Biotechnology Holding Ltd (ZYBT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Zhengye Biotechnology Holding Ltd (ZYBT) Institutional Confidence - TradingKey
Zhengye Biotechnology Holding Ltd (ZYBT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Zhengye Biotechnology Holding Ltd - TradingKey
Zhengye Biotechnology receives Nasdaq bid price deficiency notice By Investing.com - Investing.com Australia
Zhengye Biotechnology receives Nasdaq bid price deficiency notice - Investing.com UK
Zhengye Biotechnology Receives Nasdaq Letter for Minimum Bid Price Deficiency - marketscreener.com
Zhengye Biotechnology Faces Nasdaq Minimum Bid Price Deficiency After May 29 Notice - TipRanks
Zhengye Biotech has 6 months to lift stock back above $1 - Stock Titan
Zhengye Biotech's Nasdaq Lifeline: A 180-Day Race Against Financial Reality - BriefGlance
ZYBTZhengye Biotechnology Holding Ltd Stock Price and Quote - Finviz
ZYBT Stock Price, Quote & Chart | ZHENGYE BIOTECHNOLOGY-A (NASDAQ:ZYBT) - ChartMill
TradingKey - TradingKey
Zhengye (ZYBT) quarterly report delayed as CEO highlights strategic priorities; investors await key financial data. - The Legal Advocate
Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results - Tirto.id
China hog slump hits Zhengye as vaccine maker posts annual loss - Stock Titan
How risky is Zhengye (ZYBT) stock investment? (Institutional Selling) 2026-04-27Earnings Beat Stocks - newser.com
ZYBT Price Today: Zhengye Biotechnology Holding Limited Stock Price, Quote & Chart | MEXC - MEXC Exchange
Why Zhengye (ZYBT) Stock Could Rise (+3.79%) 2026-04-20Retail Picks - newser.com
Aiden Han Net Worth (2026) - GuruFocus
Wei Lian Net Worth (2026) - GuruFocus
Zhongyao Liu Net Worth (2026) - GuruFocus
Wenhua Sun Net Worth (2026) - GuruFocus
Zhengye Biotechnology posts $0.24 EPS $186M revenue no estimatesShort-Term Outlook - The Legal Advocate
Trading Recap: Will Zhengye Biotechnology Holding Limited stock hit new highs in YEARQuarterly Trade Summary & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Zhengye Biotechnology implements dual-class share structure - Investing.com
Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure - Weekly Voice
Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure Effective April 7, 2026 - Quiver Quantitative
Zhengye's new share classes give some holders 20 votes each - Stock Titan
ZYBT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
ZYBT Technical Analysis & Stock Price Forecast - Intellectia AI
Death Cross: How does Zhengye Biotechnology Holding Limited correlate with NasdaqInflation Watch & Stock Timing and Entry Methods - baoquankhu1.vn
Zhengye Biotechnology Shareholders Approve Governance and Share Structure Changes at March 24 AGM - TipRanks
Why Faraday Future Intelligent Electric Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket - Benzinga
$Zhengye Biotechnology (ZYBT.US)$ still hodl some for moon - Moomoo
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Kyverna Therapeutics (NASDAQ:KYTX) and Zhengye Biotechnology (NASDAQ:ZYBT) Critical Contrast - Defense World
ZYBT Should I Buy - Intellectia AI
Zhengye Biotechnology Director Resigns, Nasdaq Independence Deficiency to Be Addressed at March AGM - TipRanks
Zhengye Biotechnology Holding Limited Announces Resignation of Wenbin Wang as Independent Director, Member of Committees, and Chairperson of the Compensation Committee, Effective February 18, 2026 - marketscreener.com
Will Zhengye Biotechnology Holding Limited benefit from geopolitical trendsChart Signals & Trade Opportunity Analysis Reports - mfd.ru
Zhengye Biotech chairman outlines 2025 achievements, 2026 strategy By Investing.com - Investing.com South Africa
Zhengye Biotechnology Holding Limited Issues 2026 Chairman’s Letter to Shareholders - GlobeNewswire
Pullback Watch: What is the Moat Score of Bold Eagle Acquisition Corp Equity RightEarnings Overview Report & Real-Time Buy Signal Alerts - baoquankhu1.vn
Aug Closing: Does Zhengye Biotechnology Holding Limited have a sustainable dividendJobs Report & Reliable Price Breakout Alerts - baoquankhu1.vn
Franklin Templeton Asset Management India Private Limited Ranks High in Smart Money TrackerProfit Target & Stepwise Trade Signal Guides - Улправда
Published on: 2026-01-08 23:11:28 - Улправда
Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) Sees Large Decline in Short Interest - Defense World
0.15%
1.95%
자본화:
|
볼륨(24시간):